Text Size

Use of Topotecan in Patients With Refractory Acute Leukemia

This study has been completed.
Sponsor:
Collaborators:
Immunex Corporation
SmithKline Beecham
Amgen
Information provided by:
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00100477
First received: December 30, 2004
Last updated: January 20, 2009
Last verified: December 2004
History of Changes
  Purpose

The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).


Condition Intervention Phase
Leukemia
Non-Hodgkin's Lymphoma
 Drug: Topotecan
Drug: Mitozantrone
Drug: Etoposide
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia

Resource links provided by NLM:

MedlinePlus related topics: Leukemia Lymphoma
U.S. FDA Resources

Further study details as provided by Department of Veterans Affairs:

Study Start Date: December 1998
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • Patients in the following disease categories will be considered eligible for this study: *Any acute leukemia beyond an initial attempt to induce a remission or after relapse, *Chronic Myelogenous Leukemia in Blast Phase, *Refractory Multiple Myeloma, *Refractory non-Hodgkin's and Hodgkin's Lymphoma
  • Patients must be more than 14 days beyond prior myelotoxic chemotherapy.
  • Several other eligibility criteria apply.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00100477

Locations
United States, Florida
Malcolm Randall VA Medical Center
Gainesville, Florida, United States, 32608
Sponsors and Collaborators
Department of Veterans Affairs
Immunex Corporation
SmithKline Beecham
Amgen
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00100477     History of Changes
Other Study ID Numbers: CADE-RCD1
Study First Received: December 30, 2004
Last Updated: January 20, 2009
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Leukemia
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Etoposide
Mitoxantrone
Topotecan
Antineoplastic Agents, Phytogenic
 Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 16, 2013